Bright Minds’ broad portfolio of new chemical entities (NCEs) are positioned to treat a variety of pain indications, seizures, and neuropsychiatric disorders.
We are a biotechnology company dedicated to developing next-generation therapeutics to improve the lives of patients with severe and life-altering brain diseases.
